Ca2+-Mg2+-ATPase activity and ionized calcium in Type 2 diabetic patients with neuropathy

Diabetes Research and Clinical Practice

Volumn 49, Issue 2-3, 2000, Pages 113-118

  Migdalis, I N ^a   Xenos, K ^a   Chairopoulos, K ^a   Varvarigos, N ^a   Leontiades, E ^a   Karmaniolas, K ^a  

^a NIMTS HOSPITAL   (Greece)

Author keywords

Ca2+ Mg2+ ATPase activity; Peripheral neuropathy; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM ION; HEMOGLOBIN A1C; MAGNESIUM ION;

ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME ACTIVITY; ERYTHROCYTE DEFORMABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL NEUROPATHY;

BLOOD GLUCOSE; CA(2+) MG(2+)-ATPASE; CALCIUM; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; REFERENCE VALUES;

EID: 0033839498     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(00)00150-9     Document Type: Article

References (30)

1. Tooke J.E. Endothelium the main actor or choreographer in the remodelling of the retinal microvascular in diabetes? Diabetologia. 39:1996;745-746.
2. Noon J.P., Walker B.R., Webb D.J., Shore D.J., Holton A.C., Edwards D.W. et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J. Clin. Invest. 99:1997;1873-1879.
3. Tesfaye S., Harris N., Jakubowski J.J., Mody C., Wilson R.M., Renme I.G. et al. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve physiology and fluorescein angiography. Diabetologia. 36:1993;1266-1274.
4. Young M.J., Bennett J.L., Liderth S.A., Veves A., Boulton A.J.M., Douglas J.T. Rheological and microvascular parameters in diabetic peripheral neuropathy. Clin. Sci. 90:1996;183-187.
5. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 46(Suppl 2):1997;S31-S37.
6. Dejgaard A. Pathophysiology and treatment of diabetic neuropathy. Diabetic Med. 15:1998;97-112.
7. Jaap A.J., Tooke J.E. Pathophysiology of microvascular disease in non-insulin-dependent diabetes. Clin. Sci. 89:1995;3-12.
8. Jaap A.J., Shore A.C., Tooke J.E. Differences in microvascular fluid permeability between long-duration type 1 (insulin-dependent) diabetic patients with and without significant microangiopathy. Clin. Sci. 90:1996;113-117.
9. WHO Study Group, Diabetes Mellitus. Technical Report Series 727, Geneva: World Health Organization, 1985.
10. Dyck P.J. Detection, characterization and staging of polyneuropathy. Muscle Nerve. 11:1988;21-32.
11. 1c. Clin. Chem. 23:1985;882-884.
12. Larson L., Ohman S. Effect of silicone-separator tube and storage time in ionized calcium in serum. Clin. Chem. 31:1985;169-170.
13. Rizzoli R., Vadas L., Bonjour J.P. Determination of circulating parathyroid hormone. Nucl. Med. Biol. 17:1990;645-650.
14. ++-transpor ATPase by phenothiazines and butyrophenones. Bioch. Biophys. Res. Commun. 94:1980;674-681.
15. Gietzen K., Adamczyk-Engelmann A., Wuthrich A., Konstantinova A., Bader H. Compound 48/80 is a selective and powerful inhibitor of calmodulin-regulated functions. Bioch. Biophys. Acta. 736:1983;109-118.
16. Lin T.J., Morales M.F. Application of one-step procedure for measuring inorganic phosphate in the presence of protein. Anal. Biochem. 77:1977;10-17.
17. Ross E., Schatz G. Assay of protein in the presence of high concentrations of sulfhydryl compounds. Anal. Biochem. 54:1973;304-306.
18. 2+-ATPase activity of human red blood cells in healthy and diabetic volunteers. Klin. Wochenschr. 65:1987;17-21.
19. 2+-ATPase of red blood cells from diabetic patients. Klin. Wochenschr. 66:1988;443-446.
20. Dam S.V.P., Sweder V.A.B., Erkelens D.W., Marx J.J.M., Giepsen W., Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab. Rev. 11:1995;181-192.
21. Stevens M.J., Feldman E.L., Thomas T., Greene D.A. Pathogenesis of diabetic neuropathy. Veves A. Clinical Management of Diabetic Neuropathy. 1998;13-48 Humana Press, Totowa, NJ.
22. Low P.A., Schmelzer J.D., Ward K.K. Experimental hypoxic neuropathy: relevance to diabetic neuropathy. Am. J. Physiol. 250:1986b;E94-E98.
23. Newrick P.G., Wilson A.J., Jakubowski J., Boulton A.J.M., Ward J.D. Sural nerve oxygen tension in diabetes. Br. Med. J. 293:1986;1053-1054.
24. Malik R.A., Newrick P.G., Sharma A.K., Jennings A., Ah-See A.K., Mayhew T.M. et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia. 32:1989;92-102.
25. Malik R.A., Tesfaye S., Thompson S.D., Veves A., Boulton A.J.M., Ward J.D. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 36:1993;454-459.
26. Tesfaye S., Malik R.A., Ward J.D. Vascular factors in diabetic neuropathy. Diabetologia. 37:1994;847-854.
27. Levy J., Gavin J.R., Sowers J.R. Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am. J. Med. 96:1994;260-270.
28. Dyck P.J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J. Neuropathol. Exp. Neurol. 55:1995;1181-1193.
29. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 15:1992;1835-1843.
30. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab. Rev. 11:1995;193-225.